Royal Bank Of Canada 9 Meters Biopharma, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.21 - $0.32 $101 - $154	484 Added 15.61%	3,585 $1,000
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.64 $3,460 - $8,517	-13,309 Reduced 81.1%	3,101 $1,000
Q1 2022 May 16, 2022	SELL	$0.52 - $1.0 $20,141 - $38,733	-38,733 Reduced 70.24%	16,410 $9,000
Q4 2021 Feb 14, 2022	BUY	$0.85 - $1.33 $21,747 - $34,028	25,585 Added 86.56%	55,143 $53,000
Q3 2021 Nov 15, 2021	BUY	$1.03 - $1.41 $11,312 - $15,486	10,983 Added 59.13%	29,558 $38,000
Q2 2021 Aug 16, 2021	BUY	$1.04 - $1.5 $19,318 - $27,862	18,575 New	18,575 $21,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.